Payment overview · 2025
General Payments
$780.36
39 reported records · 14 companies
Healthcare provider profile · identity verified
John Matthew Ferguson, M.D.
Allopathic & Osteopathic Physicians|Family Medicine · CHARLESTON, SC · NPI 1952562969
Verified facts
What the public records show
CMS Open Payments records show John Matthew Ferguson, M.D. received $780.36 in general payments during 2025 across 39 reported records.
PFIZER INC. accounted for 25.3% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 29 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Farxiga, Jardiance, Mounjaro, Ozempic, Rybelsus.
Astellas Pharma US Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Myrbetriq as an associated drug or biological on 16 records involving 16 distinct recipient NPIs. Public Medicare Part D data also shows 58 claims for Myrbetriq by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 36 claims for Farxiga by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 23 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 147 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 196 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 39 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 113 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Rybelsus by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 90 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| PFIZER INC. | Unresolved — no canonical attribution shown | $197.60 | 25.3% | 12 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $94.89 | 12.2% | 5 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $81.52 | 10.4% | 4 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $71.43 | 9.2% | 4 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $67.36 | 8.6% | 3 | 2025 |
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $45.86 | 5.9% | 2 | 2025 |
| Hologic Sales and Service, LLC | Unresolved — no canonical attribution shown | $44.24 | 5.7% | 1 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $40.32 | 5.2% | 2 | 2025 |
| Boston Scientific Corporation | Unresolved — no canonical attribution shown | $27.26 | 3.5% | 1 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $25.35 | 3.2% | 1 | 2025 |
| Xeris Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $24.82 | 3.2% | 1 | 2025 |
| Philips North America LLC | Unresolved — no canonical attribution shown | $23.09 | 3.0% | 1 | 2025 |
| Astellas Pharma US Inc | Unresolved — no canonical attribution shown | $21.24 | 2.7% | 1 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $15.38 | 2.0% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $780.36 | 39 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $100.85 | 7 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $100.85 | 7 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $100.85 | 7 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $96.75 | 5 | 2025 |
Source payment records
|
|||||
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $81.52 | 4 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $77.74 | 4 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $77.74 | 4 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $76.74 | 4 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $56.40 | 3 | 2025 |
Source payment records
|
|||||
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $45.86 | 2 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $44.59 | 2 | 2025 |
Source payment records
|
|||||
| PROLIA Normalized: prolia |
Biological | Amgen Inc. | $44.59 | 2 | 2025 |
Source payment records
|
|||||
| FLUENT FLUID MANAGEMENT SYSTEM Normalized: fluent fluid management system |
Device | Hologic Sales and Service, LLC | $44.24 | 1 | 2025 |
Source payment records
|
|||||
| MYOSURE TISSUE REMOVAL DEVICE Normalized: myosure tissue removal device |
Device | Hologic Sales and Service, LLC | $44.24 | 1 | 2025 |
Source payment records
|
|||||
| NOVASURE Normalized: novasure |
Device | Hologic Sales and Service, LLC | $44.24 | 1 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $38.15 | 2 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $33.28 | 2 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $33.28 | 2 | 2025 |
Source payment records
|
|||||
| WaveWriter Alpha Prime 16 Normalized: wavewriter alpha prime 16 |
Device | Boston Scientific Corporation | $27.26 | 1 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $25.35 | 1 | 2025 |
Source payment records
|
|||||
| GVOKE HYPOPEN Normalized: gvoke hypopen |
Drug | Xeris Pharmaceuticals, Inc. | $24.82 | 1 | 2025 |
Source payment records
|
|||||
| Ambulatory Monitoring & Diagnostics Undivided Normalized: ambulatory monitoring diagnostics undivided |
Device | Philips North America LLC | $23.09 | 1 | 2025 |
Source payment records
|
|||||
| KRYSTEXXA Normalized: krystexxa |
Biological | Amgen Inc. | $22.77 | 1 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $21.83 | 1 | 2025 |
Source payment records
|
|||||
| Veozah Normalized: veozah |
Drug | Astellas Pharma US Inc | $21.24 | 1 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $20.01 | 1 | 2025 |
Source payment records
|
|||||
| The Cologuard Plus Collection Kit Normalized: the cologuard plus collection kit |
Device | Exact Sciences Corporation | $18.49 | 1 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Lilly USA, LLC | $17.15 | 1 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $15.38 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 90 | exact normalized | Medicare Part D |
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 36 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 147 | exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 196 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 113 | exact normalized | Medicare Part D |
| Rybelsus rybelsus |
2025 | Rybelsus | 2024 | 13 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Astellas Pharma US Inc Exact reporting entity; no affiliate inference |
2025 | Myrbetriq open payments reported associated product |
CMS Open Payments — General Payments 16 supporting records · 16 recipient NPIs · example record 1238599014 |
Myrbetriq · 2024 Exact normalized brand match · 1 Part D row |
58 | 12 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
36 | suppressed by CMS |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
23 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
147 | 33 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
196 | 37 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
39 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
113 | 28 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
90 | 21 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Rosuvastatin Calcium | Rosuvastatin Calcium | 458 | 144 |
| Atorvastatin Calcium | Atorvastatin Calcium | 455 | 145 |
| Amlodipine Besylate | Amlodipine Besylate | 427 | 123 |
| Levothyroxine Sodium | Levothyroxine Sodium | 336 | 88 |
| Lisinopril | Lisinopril | 283 | 78 |
| Gabapentin | Gabapentin | 258 | 82 |
| Losartan Potassium | Losartan Potassium | 234 | 70 |
| Omeprazole | Omeprazole | 217 | 66 |
| Metformin Hcl | Metformin Hcl | 200 | 64 |
| Mounjaro | Tirzepatide | 196 | 37 |
| Tamsulosin Hcl | Tamsulosin Hcl | 175 | 52 |
| Hydrochlorothiazide | Hydrochlorothiazide | 171 | 54 |
| Pantoprazole Sodium | Pantoprazole Sodium | 169 | 59 |
| Metformin Hcl Er | Metformin Hcl | 168 | 57 |
| Duloxetine Hcl | Duloxetine Hcl | 157 | 43 |
| Lorazepam | Lorazepam | 152 | 27 |
| Jardiance | Empagliflozin | 147 | 33 |
| Metoprolol Succinate | Metoprolol Succinate | 141 | 45 |
| Simvastatin | Simvastatin | 138 | 37 |
| Allopurinol | Allopurinol | 128 | 35 |
| Alprazolam | Alprazolam | 127 | 21 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 125 | 28 |
| Trazodone Hcl | Trazodone Hcl | 119 | 41 |
| Ozempic | Semaglutide | 113 | 28 |
| Furosemide | Furosemide | 111 | 36 |
| Tramadol Hcl | Tramadol Hcl | 110 | 28 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 107 | 41 |
| Zolpidem Tartrate | Zolpidem Tartrate | 107 | 22 |
| Naproxen | Naproxen | 101 | 37 |
| Pravastatin Sodium | Pravastatin Sodium | 95 | 22 |
| Eliquis | Apixaban | 90 | 21 |
| Tizanidine Hcl | Tizanidine Hcl | 89 | 37 |
| Citalopram Hbr | Citalopram Hydrobromide | 88 | 22 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 86 | 11 |
| Celecoxib | Celecoxib | 84 | 32 |
| Clonazepam | Clonazepam | 84 | 13 |
| Famotidine | Famotidine | 84 | 26 |
| Fluticasone Propionate | Fluticasone Propionate | 83 | 42 |
| Sertraline Hcl | Sertraline Hcl | 81 | 21 |
| Pregabalin | Pregabalin | 80 | 24 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 77 | 28 |
| Montelukast Sodium | Montelukast Sodium | 76 | 22 |
| Bupropion Xl | Bupropion Hcl | 71 | 20 |
| Metoprolol Tartrate | Metoprolol Tartrate | 71 | 26 |
| Carvedilol | Carvedilol | 69 | 17 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 69 | 14 |
| Potassium Chloride | Potassium Chloride | 68 | 20 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 65 | 23 |
| Diclofenac Sodium | Diclofenac Sodium | 64 | 30 |
| Meloxicam | Meloxicam | 64 | 18 |
| Escitalopram Oxalate | Escitalopram Oxalate | 63 | 25 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 61 | 14 |
| Myrbetriq | Mirabegron | 58 | 12 |
| Spironolactone | Spironolactone | 57 | 17 |
| Atenolol | Atenolol | 56 | 13 |
| Pioglitazone Hcl | Pioglitazone Hcl | 52 | 18 |
| Clopidogrel | Clopidogrel Bisulfate | 51 | 17 |
| Quetiapine Fumarate | Quetiapine Fumarate | 49 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 47 | 28 |
| Mirtazapine | Mirtazapine | 46 | 14 |
| Benazepril Hcl | Benazepril Hcl | 45 | 14 |
| Finasteride | Finasteride | 44 | suppressed |
| Memantine Hcl | Memantine Hcl | 43 | 11 |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 40 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 40 | 14 |
| Trulicity | Dulaglutide | 39 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 38 | 14 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 38 | suppressed |
| Indapamide | Indapamide | 38 | 12 |
| Buspirone Hcl | Buspirone Hcl | 36 | suppressed |
| Ezetimibe | Ezetimibe | 36 | 14 |
| Farxiga | Dapagliflozin Propanediol | 36 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 36 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 36 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 34 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 34 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 34 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 33 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 32 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 31 | 11 |
| Diazepam | Diazepam | 31 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 31 | 13 |
| Estradiol | Estradiol | 31 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 31 | suppressed |
| Colchicine | Colchicine | 30 | 11 |
| Humulin R | Insulin Regular, Human | 30 | suppressed |
| Ketoconazole | Ketoconazole | 30 | 19 |
| Ondansetron Odt | Ondansetron | 30 | 17 |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 29 | suppressed |
| Prednisone | Prednisone | 29 | 21 |
| Valsartan | Valsartan | 28 | suppressed |
| Chlorthalidone | Chlorthalidone | 27 | suppressed |
| Dextroamphetamine-Amphet Er | Dextroamphetamine/Amphetamine | 27 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 27 | 23 |
| Amitriptyline Hcl | Amitriptyline Hcl | 26 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 26 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 26 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 26 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 24 | suppressed |
| Januvia | Sitagliptin Phosphate | 23 | suppressed |
| Lidocaine | Lidocaine | 23 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 23 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 22 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 22 | suppressed |
| Irbesartan | Irbesartan | 21 | suppressed |
| Nystatin | Nystatin | 21 | suppressed |
| Spiriva Respimat | Tiotropium Bromide | 21 | suppressed |
| Telmisartan | Telmisartan | 21 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 20 | suppressed |
| Topiramate | Topiramate | 20 | suppressed |
| Amlodipine-Valsartan | Amlodipine Besylate/Valsartan | 19 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 19 | suppressed |
| Klor-Con M20 | Potassium Chloride | 19 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 19 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 19 | suppressed |
| Xarelto | Rivaroxaban | 19 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 18 | suppressed |
| Fenofibrate | Fenofibrate | 17 | suppressed |
| Fluconazole | Fluconazole | 17 | 13 |
| Glimepiride | Glimepiride | 17 | suppressed |
| Repatha Sureclick | Evolocumab | 17 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 16 | 11 |
| Aripiprazole | Aripiprazole | 16 | suppressed |
| Carisoprodol | Carisoprodol | 16 | suppressed |
| Glipizide | Glipizide | 16 | suppressed |
| Nifedipine Er | Nifedipine | 16 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 16 | suppressed |
| Synthroid | Levothyroxine Sodium | 16 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 15 | suppressed |
| Cyanocobalamin Injection | Cyanocobalamin (Vitamin B-12) | 15 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 15 | suppressed |
| Janumet Xr | Sitagliptin Phos/Metformin Hcl | 15 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 15 | suppressed |
| Alfuzosin Hcl Er | Alfuzosin Hcl | 14 | suppressed |
| Novolog Flexpen | Insulin Aspart | 14 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 14 | suppressed |
| Amlodipine-Olmesartan | Amlodipine Bes/Olmesartan Med | 13 | suppressed |
| Baclofen | Baclofen | 13 | suppressed |
| Dutasteride | Dutasteride | 13 | suppressed |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 13 | suppressed |
| Rybelsus | Semaglutide | 13 | suppressed |
| Zolpidem Tartrate Er | Zolpidem Tartrate | 13 | suppressed |
| Benazepril-Hydrochlorothiazide | Benazepril/Hydrochlorothiazide | 12 | suppressed |
| Ibuprofen | Ibuprofen | 12 | suppressed |
| Methylphenidate Er | Methylphenidate Hcl | 12 | suppressed |
| Movantik | Naloxegol Oxalate | 12 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 12 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 12 | suppressed |
| Clonidine | Clonidine | 11 | suppressed |
| Glipizide Er | Glipizide | 11 | suppressed |
| Oxcarbazepine | Oxcarbazepine | 11 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $780.36 · 39 records | PFIZER INC. | ABRYSVO, AREXVY, Ambulatory Monitoring & Diagnostics Undivided, COMIRNATY, Cologuard Collection Kit, Dexcom G6 Transmitter, ELIQUIS, EVENITY, FARXIGA, FLUENT FLUID MANAGEMENT SYSTEM, FREESTYLE LIBRE 3, GVOKE HYPOPEN, JARDIANCE, KRYSTEXXA, MOUNJARO, MYOSURE TISSUE REMOVAL DEVICE, NOVASURE, NURTEC ODT, Ozempic, PREVNAR 20, PROLIA, Rybelsus, SHINGRIX, The Cologuard Plus Collection Kit, Veozah, WaveWriter Alpha Prime 16, Wegovy, ZAVZPRET, ZEPBOUND | 9 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with Astellas Pharma US Inc?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error